MARCH6
E3 ubiquitin-protein ligase MARCH6
Protein Summary
E3 ubiquitin-protein ligase that promotes ubiquitination of DIO2, leading to its degradation. E3 ubiquitin ligases accept ubiquitin from an E2 ubiquitin-conjugating enzyme in the form of a thioester and then directly transfer the ubiquitin to targeted substrates. May cooperate with UBE2G1. This gene encodes a member of a family of membrane-associated E3 ubiquitin ligases containing RING-CH-type zinc finger motifs. Ubiquitination of type II deiodinase by the encoded protein is an important regulatory step in thyroid hormone signalling. Alternatively spliced transcript variants encoding multiple isoforms have been observed for this gene. [provided by RefSeq, Jul 2012]
- ENST00000274140
- ENSP00000274140
- ENSG00000145495
- ENST00000449913
- ENSP00000414643
- ENST00000503788
- ENSP00000425930
- KIAA0597
- RNF176
- TEB4
- TEB4
- DOA10
- RNF176
- MARCH-VI
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
|---|---|---|---|
disease perturbation | 1 | ||
kinase perturbation | 0.96 | ||
virus perturbation | 0.94 | ||
transcription factor perturbation | 0.91 | ||
histone modification site profile | 0.82 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 92.31 (req: < 5)
Gene RIFs: 17 (req: <= 3)
Antibodies: 138 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 92.31 (req: >= 5)
Gene RIFs: 17 (req: > 3)
Antibodies: 138 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 11
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligand: 0
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0